The human genome produces a large and complex repertoire of RNA molecules. Although only a relatively small proportion of genomic transcripts encode proteins, extensive transcription occurs throughout the genome, generating numerous non-coding RNAs.

Long non-coding RNAs are generally defined as transcripts longer than 200 nucleotides that do not encode functional proteins as their primary biological product.

The discovery of thousands of lncRNAs has substantially changed the understanding of gene regulation. Rather than being transcriptional by-products, many lncRNAs participate in highly specific cellular processes.

LncRNAs can regulate gene expression through interactions with chromatin-modifying complexes, transcription factors, messenger RNAs, microRNAs, and signaling proteins.

Their biological functions include regulation of chromatin structure, transcription, RNA splicing, mRNA stability, translation, cellular localization, and protein activity.

Abnormal lncRNA expression has been observed in numerous human diseases. Some lncRNAs promote disease progression, whereas others exert protective or tumor-suppressive functions.

Their tissue-specific expression patterns make them particularly attractive candidates for disease biomarkers.

This review discusses the molecular characteristics and mechanisms of lncRNAs and examines their contribution to human disease progression.

2. Classification of Long Non-Coding RNAs

LncRNAs can be classified according to their genomic location and relationship with protein-coding genes.

Major categories include:

1. Intergenic lncRNAs – located between protein-coding genes.
2. Intronic lncRNAs – derived primarily from intronic regions.
3. Antisense lncRNAs – transcribed from the opposite strand of protein-coding genes.
4. Sense lncRNAs – overlap protein-coding genes on the same strand.
5. Bidirectional lncRNAs – transcribed near protein-coding genes in opposite directions.
6. Enhancer-associated lncRNAs – produced from enhancer regions.

This structural diversity contributes to the wide range of biological functions performed by lncRNAs.

3. Molecular Characteristics of lncRNAs

Many lncRNAs undergo molecular processing similar to messenger RNAs.

They may undergo:

• 5′ capping;
• splicing;
• polyadenylation;
• nuclear export; and
• degradation through RNA-processing pathways.

However, not all lncRNAs exhibit identical processing patterns.

Some lncRNAs remain predominantly within the nucleus, whereas others are transported into the cytoplasm.

Their cellular localization is closely related to their function.

Nuclear lncRNAs frequently participate in chromatin remodeling and transcriptional regulation, whereas cytoplasmic lncRNAs can regulate mRNA stability, translation, signaling pathways, and microRNA activity.

4. Mechanisms of lncRNA-Mediated Gene Regulation

LncRNAs regulate gene expression through multiple molecular mechanisms.

They can function as:

• Molecular scaffolds
• Molecular guides
• Molecular decoys
• Competing endogenous RNAs
• Chromatin regulators
• Transcriptional regulators

Because individual lncRNAs can interact with multiple molecular partners, they may influence several signaling pathways simultaneously.

5. LncRNAs as Molecular Scaffolds

Some lncRNAs function as molecular scaffolds by bringing proteins or protein complexes into close proximity.

For example, lncRNAs can recruit chromatin-modifying enzymes to specific genomic regions.

This can alter histone modifications and DNA methylation patterns, thereby regulating gene transcription.

Through this mechanism, lncRNAs can establish stable or reversible changes in cellular gene expression.

6. LncRNAs as Molecular Guides

LncRNAs can guide regulatory proteins to specific DNA or RNA molecules.

Nuclear lncRNAs may interact with transcription factors or chromatin-modifying proteins and direct them to specific genomic loci.

This provides a mechanism through which lncRNAs can produce gene-specific regulatory effects.

7. LncRNAs as Molecular Decoys

Some lncRNAs act as molecular decoys by binding transcription factors, RNA-binding proteins, or other regulatory molecules.

By sequestering these molecules, lncRNAs can prevent them from interacting with their normal targets.

This mechanism allows lncRNAs to modify transcription and post-transcriptional regulation.

8. LncRNAs and MicroRNA Regulation

Certain lncRNAs can interact with microRNAs.

In the competing endogenous RNA model, a lncRNA may bind microRNAs and reduce their availability to interact with target messenger RNAs.

This can increase expression of microRNA-regulated genes.

Although the biological importance of individual competing endogenous RNA interactions varies according to cellular concentration and binding context, this mechanism remains an important area of lncRNA research.

9. LncRNAs and Epigenetic Regulation

LncRNAs are closely associated with epigenetic mechanisms.

They can interact with:

• DNA methyltransferases;
• Histone-modifying enzymes;
• Chromatin-remodeling complexes;
• Transcription factors; and
• Polycomb-associated proteins.

Through these interactions, lncRNAs can influence chromatin accessibility and gene transcription.

Abnormal epigenetic regulation mediated by lncRNAs may contribute to disease progression.

10. LncRNAs in Cancer

Cancer is one of the most extensively studied disease areas involving lncRNAs.

Tumor cells undergo profound changes in gene expression, metabolism, proliferation, apoptosis, and cellular differentiation.

LncRNAs can influence many of these processes.

Depending on their molecular functions, lncRNAs may act as oncogenes or tumor suppressors.

Dysregulated lncRNAs have been identified in breast, lung, colorectal, liver, prostate, gastric, ovarian, and hematological malignancies.

11. LncRNAs and Cancer Cell Proliferation

Uncontrolled cellular proliferation is a defining feature of cancer.

Several lncRNAs regulate cell-cycle proteins and signaling pathways involved in proliferation.

LncRNAs may influence cyclin expression, transcription-factor activity, and growth-factor signaling.

Aberrant activation of these mechanisms can promote continued cell division.

12. LncRNAs and Apoptosis

Apoptosis is an important mechanism for eliminating damaged or abnormal cells.

Cancer cells frequently develop mechanisms that suppress apoptosis.

LncRNAs can influence intrinsic and extrinsic apoptotic pathways by regulating expression or activity of apoptosis-related proteins.

Some lncRNAs promote apoptosis and therefore act as tumor suppressors, whereas others inhibit apoptosis and contribute to cancer progression.

13. LncRNAs and Cancer Metastasis

Metastasis requires cancer cells to acquire migratory and invasive properties.

LncRNAs participate in epithelial-to-mesenchymal transition, extracellular matrix remodeling, cell adhesion, and cytoskeletal organization.

Through these mechanisms, lncRNAs can influence tumor-cell migration and invasion.

Certain lncRNAs have also been associated with metastatic progression and poor clinical outcomes.

14. LncRNAs and Angiogenesis

Tumors require an adequate blood supply to support continued growth.

LncRNAs can regulate angiogenic signaling by influencing vascular endothelial growth factor expression and endothelial-cell behavior.

Dysregulated lncRNA expression may therefore promote formation of new blood vessels within tumors.

15. LncRNAs and Drug Resistance

Therapeutic resistance is a major challenge in cancer treatment.

LncRNAs can influence drug sensitivity by regulating apoptosis, DNA repair, drug transport, cellular metabolism, and survival signaling.

Some lncRNAs have been associated with resistance to chemotherapy, targeted therapy, endocrine therapy, and other anticancer treatments.

Understanding these mechanisms may help identify biomarkers for treatment response.

16. LncRNAs in Cardiovascular Disease

LncRNAs are increasingly recognized as regulators of cardiovascular biology.

They participate in:

• Vascular endothelial function;
• Smooth-muscle-cell proliferation;
• Cardiac hypertrophy;
• Fibrosis;
• Angiogenesis;
• Lipid metabolism; and
• Inflammatory signaling.

Altered lncRNA expression has been reported in atherosclerosis, myocardial infarction, heart failure, and cardiac remodeling.

17. LncRNAs and Atherosclerosis

Atherosclerosis involves lipid accumulation, endothelial dysfunction, immune-cell activation, and vascular inflammation.

LncRNAs can regulate cholesterol metabolism and inflammatory signaling in vascular cells and macrophages.

Some lncRNAs influence expression of genes involved in lipid uptake, cholesterol efflux, and macrophage activation.

Consequently, lncRNA dysregulation may contribute to atherosclerotic plaque development.

18. LncRNAs in Cardiac Remodeling

Cardiac injury can result in hypertrophy, fibrosis, and structural remodeling.

LncRNAs regulate signaling pathways involved in cardiomyocyte growth and fibroblast activation.

Abnormal expression of specific lncRNAs may therefore contribute to pathological cardiac hypertrophy and fibrosis.

Because some lncRNAs display tissue-specific expression, they may have potential as biomarkers for cardiac disease.

19. LncRNAs in Metabolic Disorders

Metabolic diseases are associated with changes in gene expression and cellular signaling.

LncRNAs participate in:

• Glucose metabolism;
• Lipid metabolism;
• Insulin signaling;
• Adipocyte differentiation;
• Inflammation; and
• Energy homeostasis.

Altered lncRNA expression has been associated with obesity, insulin resistance, type 2 diabetes, and metabolic liver disease.

20. LncRNAs and Obesity

Adipose tissue is an important endocrine and metabolic organ.

LncRNAs can regulate adipocyte differentiation and lipid storage.

Changes in lncRNA expression may influence the balance between adipogenesis, lipolysis, and energy expenditure.

Some lncRNAs also regulate inflammatory responses within adipose tissue.

These mechanisms may contribute to obesity-associated metabolic dysfunction.

21. LncRNAs and Type 2 Diabetes

Pancreatic β-cells require precise regulation of gene expression to maintain insulin production and secretion.

LncRNAs can influence β-cell development, survival, and insulin secretion.

In peripheral tissues, lncRNAs may regulate insulin signaling and glucose uptake.

Therefore, abnormal lncRNA activity may contribute to both β-cell dysfunction and insulin resistance.

22. LncRNAs in Liver Disease

The liver performs essential functions in glucose, lipid, and protein metabolism.

LncRNAs regulate hepatocyte metabolism, inflammatory responses, fibrosis, and cellular survival.

Abnormal lncRNA expression has been observed in fatty liver disease, viral liver disease, fibrosis, and hepatocellular carcinoma.

Some lncRNAs can promote hepatic lipid accumulation and inflammatory signaling, whereas others may have protective functions.

23. LncRNAs in Neurodegenerative Diseases

The nervous system contains extensive non-coding RNA activity.

LncRNAs participate in neuronal differentiation, synaptic function, axonal development, and cellular survival.

Altered lncRNA expression has been associated with Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and other neurological disorders.

Because neurons are highly dependent on precise gene regulation, disruption of lncRNA networks may have significant consequences.

24. LncRNAs in Alzheimer's Disease

Alzheimer's disease involves progressive neuronal dysfunction and degeneration.

Molecular mechanisms include abnormal amyloid processing, tau pathology, oxidative stress, mitochondrial dysfunction, and neuroinflammation.

LncRNAs may regulate several of these processes.

Some lncRNAs influence amyloid precursor protein processing, while others affect neuronal survival and inflammatory signaling.

LncRNAs may therefore contribute to disease progression through multiple molecular pathways.

25. LncRNAs in Parkinson's Disease

Parkinson's disease is associated with degeneration of dopaminergic neurons.

LncRNAs have been investigated in relation to mitochondrial function, oxidative stress, apoptosis, and neuroinflammation.

Abnormal lncRNA expression may influence survival pathways in dopaminergic neurons.

Further research is needed to establish which lncRNAs have causal roles and which represent secondary changes associated with disease progression.

26. LncRNAs and Autoimmune Disease

Immune-system activity is tightly regulated by gene expression.

LncRNAs can influence immune-cell differentiation, cytokine production, and inflammatory signaling.

Dysregulated lncRNAs have been investigated in rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, and other immune-mediated disorders.

Some lncRNAs may regulate NF-κB, JAK/STAT, and other inflammatory pathways.

27. LncRNAs and Fibrosis

Fibrosis occurs when excessive extracellular matrix accumulates following chronic tissue injury.

LncRNAs can regulate fibroblast activation and transforming growth factor-beta signaling.

Abnormal lncRNA expression has been implicated in liver, kidney, lung, and cardiac fibrosis.

Through regulation of fibroblast proliferation and extracellular matrix production, lncRNAs may influence progression from chronic inflammation to irreversible tissue remodeling.

28. LncRNAs and Inflammation

LncRNAs participate in both acute and chronic inflammatory responses.

They can regulate cytokine production, immune-cell activation, and transcription factors.

Some lncRNAs enhance inflammatory signaling, whereas others suppress it.

The balance between these activities is important for maintaining tissue homeostasis.

Persistent dysregulation may contribute to chronic inflammatory disease.

29. LncRNAs as Disease Biomarkers

The tissue-specific expression and relative stability of certain lncRNAs have generated interest in their diagnostic applications.

LncRNAs can potentially be detected in:

• Blood;
• Plasma;
• Serum;
• Urine;
• Cerebrospinal fluid; and
• Tissue samples.

Some lncRNAs may distinguish diseased from healthy individuals or provide information about disease stage and prognosis.

However, clinical translation requires standardized detection methods, large validation cohorts, and reproducible reference standards.

30. LncRNAs in Precision Medicine

The diversity of lncRNA expression patterns may provide opportunities for personalized medicine.

Disease-associated lncRNA profiles could potentially be used to classify patients according to molecular disease subtypes.

In cancer, for example, lncRNA signatures may provide information about prognosis or treatment response.

Combining lncRNA profiles with genomic, transcriptomic, and clinical data may improve disease stratification.

Review Design

The present study was prepared as a narrative review of published scientific evidence concerning the molecular functions of long non-coding RNAs and their contribution to human disease progression.

Literature Search

Relevant scientific literature was evaluated using biomedical databases and peer-reviewed journals.

Search terms included combinations of:

“long non-coding RNA,” “lncRNA,” “non-coding RNA,” “gene regulation,” “epigenetics,” “cancer,” “cardiovascular disease,” “metabolic disease,” “neurodegeneration,” “autoimmune disease,” “fibrosis,” “biomarker,” and “RNA therapeutics.”

Inclusion Criteria

Studies were considered relevant when they:

1. Investigated biological functions of lncRNAs;
2. Examined lncRNA-mediated gene regulation;
3. Investigated lncRNAs in human disease;
4. Evaluated lncRNAs as biomarkers;
5. Investigated therapeutic targeting of lncRNAs; or
6. Provided mechanistic evidence linking lncRNAs with disease progression.

Exclusion Criteria

Publications lacking substantial relevance to lncRNA biology or human disease mechanisms were excluded from the main synthesis.

Data Synthesis

The available evidence was organized according to molecular mechanisms and major disease categories, including cancer, cardiovascular disease, metabolic disorders, neurological disorders, autoimmune diseases, and fibrosis.

32. Results

The reviewed literature indicates that lncRNAs are important regulators of multiple cellular processes associated with human disease.

Several major findings were identified.

First, lncRNAs regulate gene expression through interactions with DNA, RNA, and proteins.

Second, nuclear lncRNAs can modify chromatin structure and transcription, whereas cytoplasmic lncRNAs can regulate mRNA stability, translation, and signaling pathways.

Third, abnormal lncRNA expression is associated with cancer progression through effects on proliferation, apoptosis, invasion, metastasis, angiogenesis, and drug resistance.

Fourth, lncRNAs participate in cardiovascular and metabolic processes, including lipid metabolism, insulin signaling, vascular inflammation, and cardiac remodeling.

Fifth, altered lncRNA expression is associated with neurological disorders through effects on neuronal survival, mitochondrial function, inflammation, and synaptic regulation.

Sixth, lncRNAs can regulate immune responses and fibrosis.

Finally, disease-associated lncRNAs have potential applications as diagnostic, prognostic, and therapeutic targets.

33. Therapeutic Perspectives

Antisense Oligonucleotides

Antisense oligonucleotides can be designed to bind specific lncRNAs and promote their degradation or interfere with their function.

This approach may be particularly useful for disease-promoting lncRNAs.

Small Interfering RNAs

RNA interference-based approaches can reduce expression of selected cytoplasmic lncRNAs.

The specificity of these approaches makes them attractive candidates for experimental therapeutic development.

CRISPR-Based Strategies

CRISPR technologies provide opportunities to modify lncRNA genes or regulatory regions.

CRISPR interference and CRISPR activation approaches may allow researchers to suppress or increase lncRNA expression without necessarily altering the underlying DNA sequence.

LncRNA Replacement

For protective or tumor-suppressive lncRNAs, therapeutic strategies could theoretically restore their expression.

Such approaches remain challenging because efficient and tissue-specific delivery of large RNA molecules is required.

Nanoparticle-Based Delivery

Nanoparticle systems are being investigated for targeted delivery of RNA-based therapeutics.

Improved delivery could enhance the therapeutic potential of lncRNA-targeting strategies while reducing unwanted effects in other tissues.

Long non-coding RNAs have emerged as important components of the molecular regulatory architecture of human cells.

Their ability to interact with DNA, RNA, and proteins allows them to influence biological processes at several levels.

Unlike conventional protein-coding genes, lncRNAs can function through molecular interactions rather than through production of proteins.

This gives them considerable regulatory versatility.

One of the most important characteristics of lncRNAs is their tissue and cell-type specificity. A particular lncRNA may be highly expressed in one tissue but nearly absent in another.

This characteristic may explain why lncRNA dysregulation can produce disease-specific molecular signatures.

Cancer provides one of the clearest examples of lncRNA involvement in disease progression. Tumor-associated lncRNAs can regulate virtually every major feature of malignant progression, including uncontrolled proliferation, resistance to apoptosis, invasion, metastasis, angiogenesis, and therapeutic resistance.

However, lncRNA biology is not restricted to cancer.

In cardiovascular disease, lncRNAs influence vascular inflammation, endothelial function, cardiac hypertrophy, and fibrosis.

In metabolic disease, they regulate glucose and lipid metabolism and may contribute to insulin resistance.

In neurological disease, lncRNAs can influence neuronal survival, synaptic activity, mitochondrial function, and neuroinflammation.

The potential use of lncRNAs as biomarkers is particularly interesting. Many lncRNAs demonstrate disease-associated changes in biological fluids and tissues.

However, several challenges must be addressed before widespread clinical use.

These include differences in sample processing, RNA extraction methods, normalization strategies, detection platforms, and patient characteristics.

Another challenge is distinguishing correlation from causation. Altered lncRNA expression may be a consequence of disease rather than a driver of disease progression.

Functional studies using genetic manipulation are therefore essential for establishing biological relevance.

Therapeutic targeting presents additional challenges.

LncRNAs can have complex secondary structures and multiple molecular partners. A single lncRNA may regulate several pathways, and suppressing it could therefore produce unexpected biological effects.

Furthermore, efficient delivery of RNA-targeting molecules to specific tissues remains an important technical obstacle.

Despite these challenges, the growing understanding of lncRNA biology suggests that these molecules may become increasingly important in molecular diagnostics and therapeutics.

35. Future Perspectives

Future research should focus on identifying lncRNAs with experimentally confirmed causal roles in disease.

High-throughput sequencing combined with single-cell and spatial transcriptomic approaches may help identify disease-associated lncRNAs at cellular resolution.

Functional screening platforms can further determine which lncRNAs directly influence disease phenotypes.

Another important area is the development of standardized approaches for detecting circulating lncRNAs.

Large-scale clinical studies will be required to determine whether specific lncRNA signatures can reliably predict disease development, progression, or treatment response.

Advances in RNA delivery systems may also improve the feasibility of lncRNA-targeted therapies.

Integration of lncRNA information with genomic, epigenomic, transcriptomic, proteomic, and clinical data could ultimately contribute to personalized molecular medicine.

Long non-coding RNAs represent a major and functionally diverse component of the human transcriptome.

They regulate gene expression through interactions with chromatin, DNA, RNA, proteins, transcription factors, and signaling pathways.

Dysregulated lncRNAs have been implicated in cancer, cardiovascular disease, metabolic disorders, neurodegenerative diseases, autoimmune conditions, fibrosis, and chronic inflammation.

Their effects on cell proliferation, apoptosis, metabolism, immune signaling, oxidative stress, epithelial-to-mesenchymal transition, and tissue remodeling can influence both the initiation and progression of human disease.

The tissue specificity and disease-associated expression of lncRNAs make them promising candidates for diagnostic and prognostic applications.

At the same time, their complex molecular functions provide opportunities for therapeutic intervention through antisense oligonucleotides, RNA interference, CRISPR-based approaches, and RNA replacement strategies.

Further mechanistic and clinical studies are required to distinguish disease-driving lncRNAs from secondary molecular changes and to establish safe, effective methods for therapeutic targeting.

A deeper understanding of lncRNA biology may ultimately contribute to improved disease diagnosis, prognostic assessment, and development of precision therapeutic strategies.

1. Mattick JS, Rinn JL. Discovery and annotation of long noncoding RNAs. Nature Structural & Molecular Biology. 2015;22:5–7.
2. Quinn JJ, Chang HY. Unique features of long non-coding RNA biogenesis and function. Nature Reviews Genetics. 2016;17:47–62.
3. Statello L, Guo CJ, Chen LL, Huarte M. Gene regulation by long non-coding RNAs and its biological functions. Nature Reviews Molecular Cell Biology. 2021;22:96–118.
4. Rinn JL, Chang HY. Long noncoding RNAs: molecular modalities to organismal functions. Annual Review of Biochemistry. 2020;89:283–308.
5. Guttman M, Rinn JL. Modular regulatory principles of large non-coding RNAs. Nature. 2012;482:339–346.
6. Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nature Reviews Genetics. 2009;10:155–159.
7. Schmitt AM, Chang HY. Long noncoding RNAs: at the intersection of cancer and chromatin biology. Cold Spring Harbor Perspectives in Medicine. 2016;6:a026492.
8. Bhan A, Soleimani M, Mandal SS. Long noncoding RNA and cancer: a new paradigm. Cancer Research. 2017;77:3965–3981.
9. Huarte M. The emerging role of lncRNAs in cancer. Nature Medicine. 2015;21:1253–1261.
10. Prensner JR, Chinnaiyan AM. The emergence of lncRNAs in cancer biology. Cancer Discovery. 2011;1:391–407.
11. Batista PJ, Chang HY. Long noncoding RNAs: cellular address codes in development and disease. Cell. 2013;152:1298–1307.
12. Kopp F, Mendell JT. Functional classification and experimental dissection of long noncoding RNAs. Cell. 2018;172:393–407.
13. Yao RW, Wang Y, Chen LL. Cellular functions of long noncoding RNAs. Nature Cell Biology. 2019;21:542–551.
14. Bridges MC, Daulagala AC, Kourtidis A. LNCcation: lncRNA localization and function. Journal of Cell Biology. 2021;220:e202009045.
15. Mercer TR, Dinger ME, Sunkin SM, et al. Specific expression of long noncoding RNAs in the mouse brain. Proceedings of the National Academy of Sciences. 2008;105:716–721.
16. Ransohoff JD, Wei Y, Khavari PA. The functions and unique features of long intergenic non-coding RNA. Nature Reviews Molecular Cell Biology. 2018;19:143–157.
17. Klattenhoff CA, Scheuermann JC, Surface LE, et al. Braveheart, a long noncoding RNA required for cardiovascular lineage commitment. Cell. 2013;152:570–583.
18. Grote P, Wittler L, Hendrix D, et al. The tissue-specific lncRNA Fendrr is an essential regulator of heart and body wall development in the mouse. Developmental Cell. 2013;24:206–214.
19. Fatica A, Bozzoni I. Long non-coding RNAs: new players in cell differentiation and development. Nature Reviews Genetics. 2014;15:7–21.
20. Geisler S, Coller J. RNA in unexpected places: long non-coding RNA functions in diverse cellular contexts. Nature Reviews Molecular Cell Biology. 2013;14:699–712.
21. Boulter L, Poon IKH. Cell death and long non-coding RNAs. Cell Death & Disease. 2021;12:1–12.
22. Sun Q, Hao Q, Prasanth KV. Nuclear long noncoding RNAs: key regulators of gene expression. Trends in Genetics. 2018;34:142–157.
23. Marchese FP, Raimondi I, Huarte M. The multidimensional mechanisms of long noncoding RNA function. Genome Biology. 2017;18:206.
24. Chen LL. Linking long noncoding RNA localization and function. Trends in Biochemical Sciences. 2016;41:761–772.
25. Statello L, Guo CJ, Chen LL, Huarte M. Gene regulation by long non-coding RNAs and its biological functions. Nature Reviews Molecular Cell Biology. 2021;22:96–118.